TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33622079

Group type: EXPERIMENTAL
Intervention: Ozone bleaching with the ozone-releasing machine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemical bleaching with 40% hydrogen peroxide (H2O2) gel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 40% H2O2 gel activated with the diode laser
Number of subjects: 48
Study: 35578151

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 46
Study: 33446440

Group type: EXPERIMENTAL
Intervention: Pompage therapy (24 sessions over 8 weeks, 40 minutes each, three times a week)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 56
Study: 33734538

Group type: EXPERIMENTAL
Intervention: ENT + GC (Genetic Counseling)
Number of subjects: 49
Study: 33510567

Group type: EXPERIMENTAL
Intervention: Laparoscopic intra-abdominal ultrasound-guided radiofrequency ablation
Number of subjects: 110
Study: 36162790

Group type: EXPERIMENTAL
Intervention: Walking-focused proactive counseling intervention (6 telephone coaching sessions over 8-14 weeks)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Walking-focused proactive counseling intervention
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 380
Study: 33514367

Group type: EXPERIMENTAL
Intervention: Kaloba® liquid
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Kaloba® tablet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All arms combined
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 160
Study: 32720353

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy (OAT) continued
Number of subjects: 436

Group type: COMPARATOR
Intervention: OAT discontinued
Number of subjects: 436
Study: 36141520

Group type: EXPERIMENTAL
Intervention: Graphic pictorial cigarette warning labels
Number of subjects: 661

Group type: COMPARATOR
Intervention: Text-only labels
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios of manipulated prices
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios of graphic pictorial cigarette warning labels
Number of subjects: 661
Study: 35614518

Group type: EXPERIMENTAL
Intervention: Abdominal weight training (AWT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Abdominal weight training + cough machine (AWT + CM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 34565357

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention delivered by first-line managers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving a lecture
Number of subjects: 0
Study: 34844061

Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP) plus treatment as usual (TAU)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP)
Number of subjects: 221
Study: 33960946

Group type: EXPERIMENTAL
Intervention: Water immersion (WI)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Air insufflation (AI)
Number of subjects: 526
Study: 32401715

Group type: EXPERIMENTAL
Intervention: Combination group (lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta‐1b on alternate days for 14 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (lopinavir 400 mg and ritonavir 100 mg every 12 h for 14 days)
Number of subjects: 127
Study: 34209647

Group type: EXPERIMENTAL
Intervention: Self-guided forest therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Guided forest therapy program
Number of subjects: 37
Study: 35758850

Group type: EXPERIMENTAL
Intervention: SpikoGen® vaccine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 300
Study: 34765460

Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Bias Modification intervention
Number of subjects: 749

Group type: COMPARATOR
Intervention: Cluster 2 (41.0%, n = 307)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Cluster 3 (33.8%, n = 253)
Number of subjects: 749
Study: 36253714

Group type: EXPERIMENTAL
Intervention: 800 μg GTN administered in the catheter immediately after recanalization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline administered in the catheter immediately after recanalization
Number of subjects: 40
Study: 34761854

Group type: EXPERIMENTAL
Intervention: School-based intervention targeting nutrition environment, curricula, and community; duration of six months.
Number of subjects: 862

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 862
Study: 35378542

Group type: EXPERIMENTAL
Intervention: ImmunoCAP® fluorescence enzyme immunoassay (FEIA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ImmunoCAP® ISAC
Number of subjects: 19
Study: 32247251

Group type: EXPERIMENTAL
Intervention: Interaktor app
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 149
Study: 35788622

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (20 mg/d on days 1-5, then 10 mg/d on days 6-10)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Standard dexamethasone (6 mg/d for 10 days)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Oxygen support standard of care (o2SC)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: HFNo2
Number of subjects: 546
Study: 33331088

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32472620

Group type: EXPERIMENTAL
Intervention: Alcohol beverage sufficient to produce a breath alcohol concentration of 0.08 g/dl
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 26
Study: 35085503

Group type: EXPERIMENTAL
Intervention: Intravitreal faricimab 6.0 mg every 8 weeks
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Faricimab per personalised treatment interval (PTI)
Number of subjects: 1891

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Ocular adverse events
Number of subjects: 1891
Study: 33293225

Group type: EXPERIMENTAL
Intervention: 0.4 mm steeper lens
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Optimally fitted lens
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.4 mm flatter lens
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nasal measurement
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conjunctival staining
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comfort scoring
Number of subjects: 17
Study: 34325186

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standardized analgesia protocol (Control)
Number of subjects: 68
Study: 32830855

Group type: EXPERIMENTAL
Intervention: Clinician-patient racial/ethnic concordance
Number of subjects: 0
Study: 32651769

Group type: EXPERIMENTAL
Intervention: Proctored guidance
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simulator generated guidance
Number of subjects: 70

Group type: COMPARATOR
Intervention: No guidance
Number of subjects: 70
Study: 33256237

Group type: EXPERIMENTAL
Intervention: Cell-based therapy
Number of subjects: 0
Study: 36398328

Group type: EXPERIMENTAL
Intervention: Baby Steps Wellbeing intervention
Number of subjects: 496

Group type: COMPARATOR
Intervention: Baby Care control arm
Number of subjects: 496
Study: 34598813

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (TE)
Number of subjects: 0
Study: 32311473

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous linezolid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 900- and 1200-mg linezolid doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Doubling the standard dose of linezolid
Number of subjects: 30
Study: 35802209

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention in conjunction with behavioral treatment (BT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Behavioral treatment (BT) active control condition
Number of subjects: 58
Study: 33852940

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 36501158

Group type: EXPERIMENTAL
Intervention: 1 g/kg BM of glucose (Glu)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 g/kg BM of fructose (Fru)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg BM of glucose/fructose (GluFru)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.2 g sucralose (placebo)
Number of subjects: 16
Study: 32594615

Group type: EXPERIMENTAL
Intervention: Low-intensity 4-week anti-idling intervention (onsite signage, newsletters, fact sheets)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (2 schools)
Number of subjects: 12
Study: 32119714

Group type: EXPERIMENTAL
Intervention: Screen time (ST)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Playing outside (PO)
Number of subjects: 526
Study: 35908116

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback targeting the left medial prefrontal cortex (8 sessions of 30 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (16 sessions)
Number of subjects: 20
Study: 34859105

Group type: EXPERIMENTAL
Intervention: Ultimaster (biodegradable polymer DES)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Magmaris (magnesium bioresorbable scaffold)
Number of subjects: 362
Study: 35347281

Group type: EXPERIMENTAL
Intervention: Topical B‐VEC treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 32419310

Group type: EXPERIMENTAL
Intervention: High bicarbonate dialysate concentration (36 mmol/L)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bicarbonate dialysate concentration of 30 mmol/L (Control)
Number of subjects: 56
Study: 36420538

Group type: EXPERIMENTAL
Intervention: Presence of Pregnancy Category (PC) letters in drug labeling
Number of subjects: 162

Group type: COMPARATOR
Intervention: Absence of Pregnancy Category (PC) letters in drug labeling
Number of subjects: 162
Study: 33508990

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 60
Study: 32469870

Group type: EXPERIMENTAL
Intervention: Food supplement from pre-conception to term (PC-T)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Food supplement from mid-gestation to term (MG-T)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Routine prenatal care (RPC)
Number of subjects: 460
Study: 34476629

Group type: EXPERIMENTAL
Intervention: M1 a‐tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham group received sham tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received only physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32
Study: 33975039

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans (5 × 10^9 CFU/kg)
Number of subjects: 480
Study: 32004709

Group type: EXPERIMENTAL
Intervention: TeenBP CDS
Number of subjects: 925
Study: 33573502

Group type: EXPERIMENTAL
Intervention: Kinesthetic-experiential learning (KEL) group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Model-mastery learning (MML) group
Number of subjects: 42
Study: 33958657

Group type: EXPERIMENTAL
Intervention: Weekly iron-folic acid supplementation (WIFAS)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 226
Study: 32162567

Group type: EXPERIMENTAL
Intervention: End-fire biopsy
Number of subjects: 730

Group type: COMPARATOR
Intervention: Side-fire biopsy
Number of subjects: 730
Study: 35073890

Group type: EXPERIMENTAL
Intervention: Video Remote Interpreting (VR)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Telephone Remote Interpreting (TR)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 305
Study: 33780432

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Eating training (ET)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intensive swallowing training (IST)
Number of subjects: 83
Study: 36070638

Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg/day (OSA only), 75 mg/day, 150 mg/day, 300 mg/day
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Solriamfetol (combined doses)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 35217575

Group type: EXPERIMENTAL
Intervention: Single-agent ieramilimab
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Combination of ieramilimab and spartalizumab
Number of subjects: 255
Study: 32002617

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 59

Group type: COMPARATOR
Intervention: PORT
Number of subjects: 59
Study: 34518266

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP target <120 mm Hg, n=2371)
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP target <140 mm Hg, n=2362)
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment with standard glycaemic control
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure treatment with standard glycaemic control
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment with intensive glycaemic control
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure treatment with intensive glycaemic control
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment for those with cognitive impairment
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure treatment for those with cognitive impairment
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment for those with normal cognitive function
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure treatment for those with normal cognitive function
Number of subjects: 4733
Study: 32360887

Group type: EXPERIMENTAL
Intervention: Health Care Professional (HCP) support
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: HCP Plus Peer support
Number of subjects: 292

Group type: COMPARATOR
Intervention: HCP support
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Caregiver outcomes
Number of subjects: 292
Study: 35802187

Group type: EXPERIMENTAL
Intervention: THA assisted by a newly designed robotic arm
Number of subjects: 72

Group type: COMPARATOR
Intervention: THA with conventional surgical methods
Number of subjects: 72
Study: 32915300

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 mL of 0.375% levobupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Retrolaminar block (RLB) with 20 mL of 0.375% levobupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Retrolaminar block (RLB)
Number of subjects: 45
Study: 32401339

Group type: EXPERIMENTAL
Intervention: PACES intervention (n = 49)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control (n = 52)
Number of subjects: 101
Study: 35616265

Group type: EXPERIMENTAL
Intervention: Real MWM group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham MWM group (n = 25)
Number of subjects: 50
Study: 33175346

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 10
Study: 32140719

Group type: EXPERIMENTAL
Intervention: Seabuckthorn oil augmented in 16:1n-7t (480 mg 16:1n-7t/d)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Unmodified seabuckthorn oil (1520 mg 16:1n-7c/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 13
Study: 36000599

Group type: EXPERIMENTAL
Intervention: Consumption of processed food 1 or 2 times a month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Processed food consumption
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aflatoxin M1 levels in breast milk
Number of subjects: 90
Study: 34462346

Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation (PR)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation (PR)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Participation in ?80% of planned outpatient PR sessions
Number of subjects: 701
Study: 32397802

Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery (RIRS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Percutaneous Nephrolithotomy (PNL)
Number of subjects: 132

Group type: COMPARATOR
Intervention: PNL
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 132
Study: 36239033

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2 mg/day, adjusted to 1-10 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 32940187

Group type: EXPERIMENTAL
Intervention: Tocilizumab (monoclonal antibody against IL-6 receptors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study: 32958010

Group type: EXPERIMENTAL
Intervention: Digitally supported intervention for clinical decision making in polypharmacy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 27
Study: 37815091

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) 2×/week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High Protein Diet via Whey Protein Supplementation (PRO, 2 × 25 g whey protein isolate/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: RE + PRO
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON, 2 × 23.75 g maltodextrin/d)
Number of subjects: 33
Study: 33683019

Group type: EXPERIMENTAL
Intervention: Peramivir 600 mg repeat-dose
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg single-dose
Number of subjects: 208

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 208
Study: 35036430

Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular intervention (Control)
Number of subjects: 100
Study: 33956063

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study: 33032651

Group type: EXPERIMENTAL
Intervention: Pessary self-management
Number of subjects: 330

Group type: COMPARATOR
Intervention: Clinic-based care
Number of subjects: 330
Study: 35465686

Group type: EXPERIMENTAL
Intervention: MK‐7 (720 µg) plus vitamin D (25 µg)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 33908729

Group type: EXPERIMENTAL
Intervention: Integrated approach to the management of hypertension through the Campania Salute Network
Number of subjects: 15000
Study: 35959357

Group type: EXPERIMENTAL
Intervention: Cluster nursing combined with CDT
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine nursing combined with CDT
Number of subjects: 84
Study: 34282987

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 560
Study: 34261972

Group type: EXPERIMENTAL
Intervention: Group 1 (under 40 years)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Group 2 (above 40 years)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group 1 and Group 2
Number of subjects: 128
Study: 33269529

Group type: EXPERIMENTAL
Intervention: 0.5% minoxidil
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 54
Study: 34849957

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir 400/60 mg once-daily
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study: 34103634

Group type: EXPERIMENTAL
Intervention: GWAS analysis of asthma-associated loci
Number of subjects: 56167

Group type: EXPERIMENTAL
Intervention: TWAS analysis for lung tissue
Number of subjects: 56167

Group type: EXPERIMENTAL
Intervention: TWAS analysis for blood tissue
Number of subjects: 56167

Group type: EXPERIMENTAL
Intervention: Prioritization of druggable genes
Number of subjects: 56167
Study: 32674048

Group type: EXPERIMENTAL
Intervention: 15‐mg oral methotrexate per week
Number of subjects: 33

Group type: COMPARATOR
Intervention: 3–5‐mg/kg/day cyclosporine
Number of subjects: 33
Study: 35657955

Group type: EXPERIMENTAL
Intervention: Pilates training group (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28
Study: 32991792

Group type: EXPERIMENTAL
Intervention: Benzodiazepines with escitalopram for GAD
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Benzodiazepines with venlafaxine for MDD
Number of subjects: 640
Study: 35100916

Group type: EXPERIMENTAL
Intervention: Real Age feedback (younger)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real Age feedback (slightly older)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no Real Age feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real Age feedback (much younger)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real Age feedback (much older)
Number of subjects: 0
Study: 33411006

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 11313

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 11313

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11313
Study: 32182190

Group type: EXPERIMENTAL
Intervention: Kripalu Yoga program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 53
Study: 35080487

Group type: EXPERIMENTAL
Intervention: Added soda
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100% fruit juice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study: 33934389

Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11